Ferring Highlights Commitment to C. Diff Infection Community on the Second Anniversary of the Launch of REBYOTA® (fecal ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

FDA approved to prevent recurrent C. difficile infection (rCDI), REBYOTA is widely available with a strong drug supply and dedicated manufacturing facility Since launch, Ferring created REBYOTA ...

jslm), the first microbiome-based therapy approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent C. difficile (C. diff) infection in individuals 18 years of age ...

“Access to FDA-approved treatments to prevent recurrent C. difficile infection remains critical for halting the vicious cycle of debilitating symptoms and suffering affecting patients with this ...

“Access to FDA-approved treatments to prevent recurrent C. difficile infection remains critical for halting the vicious cycle of debilitating symptoms and suffering affecting patients with this ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...